CD8A and neoplasm: Seminal work from multiple groups has demonstrated thatstem-like CD8+ T cells, an antigen-experienced CD8+ T cell subsetthat retains the capacity for both self-renewal and further differentiation,are the primary CD8+ T cell subset that responds to therapeutic immunecheckpoint blockade (ICB).36−38 Subsequent work has demonstratedthat a niche of these stem-like CD8+ T cells is maintained in TDLNsthroughout tumor progression, in part due to the role played by migratoryDCs transiting from the tumor microenvironment to the lymph node viathe peritumoral lymphatics.39,40